Solifenacin tartrate

Drug Profile

Solifenacin tartrate

Alternative Names: HIP-1503; Solifenacin tartrate - Hanmi Pharmaceutical

Latest Information Update: 26 Oct 2016

Price : $50

At a glance

  • Originator Hanmi Pharmaceutical
  • Class Antispasmodics; Esters; Isoquinolines; Quinuclidines; Small molecules; Urologics
  • Mechanism of Action Muscarinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Overactive bladder

Most Recent Events

  • 19 Aug 2016 Phase-I clinical trials in Overactive bladder in South Korea (PO) (Hanmi Pharmaceutical pipeline, August 2016)
  • 01 May 2016 Hanmi Pharmaceutical completes a phase I trial in Overactive bladder (In volunteers) in South Korea (PO) (NCT02940314)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top